Patents Assigned to NOLIVA THERAPEUTICS LLC
  • Peptidomimetic compounds
    Patent number: 10011639
    Abstract: The present invention relates to inhibitors of protein-protein interactions (PPI). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer. Further included is the targeting of components of the BCL2 signaling pathway, specifically BCL2-A1 and MCL-1.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: July 3, 2018
    Assignee: NOLIVA THERAPEUTICS LLC
    Inventors: Renato T. Skerlj, Andrew C. Good
  • PEPTIDOMIMETIC COMPOUNDS
    Publication number: 20170037085
    Abstract: The present invention relates to inhibitors of protein-protein interactions (PPI). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer. Further included is the targeting of components of the BCL2 signaling pathway, specifically BCL2-A1 and MCL-1.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Applicant: Noliva Therapeutics LLC
    Inventors: Renato T. SKERLJ, Andrew C. GOOD
  • Peptidomimetic compounds
    Patent number: 9493510
    Abstract: The present invention relates to inhibitors of protein-protein interactions (PPI). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer. Further included is the targeting of components of the BCL2 signaling pathway, specifically BCL2-A1 and MCL-1.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: November 15, 2016
    Assignee: NOLIVA THERAPEUTICS LLC
    Inventors: Renato T. Skerlj, Andrew C. Good
  • PEPTIDOMIMETIC COMPOUNDS
    Publication number: 20150353606
    Abstract: The present invention relates to inhibitors of protein-protein interactions (PPI). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer. Further included is the targeting of components of the BCL2 signaling pathway, specifically BCL2-A1 and MCL-1.
    Type: Application
    Filed: January 10, 2014
    Publication date: December 10, 2015
    Applicant: NOLIVA THERAPEUTICS LLC
    Inventors: Renato T. Skerlj, Andrew C. Good